- Home
- TNDM vs CNTA Comparison
TNDM vs CNTA Comparison
Compare TNDM & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNDM
- CNTA
- Stock Information
- Founded
- TNDM 2006
- CNTA 2020
- Country
- TNDM United States
- CNTA United Kingdom
- Employees
- TNDM N/A
- CNTA N/A
- Industry
- TNDM Medical/Dental Instruments
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- TNDM Health Care
- CNTA Health Care
- Exchange
- TNDM Nasdaq
- CNTA Nasdaq
- Market Cap
- TNDM 1.9B
- CNTA 2.2B
- IPO Year
- TNDM 2013
- CNTA 2021
- Fundamental
- Price
- TNDM $27.34
- CNTA $16.00
- Analyst Decision
- TNDM Buy
- CNTA Strong Buy
- Analyst Count
- TNDM 16
- CNTA 7
- Target Price
- TNDM $52.50
- CNTA $23.71
- AVG Volume (30 Days)
- TNDM 1.6M
- CNTA 463.7K
- Earning Date
- TNDM 11-06-2024
- CNTA 11-12-2024
- Dividend Yield
- TNDM N/A
- CNTA N/A
- EPS Growth
- TNDM N/A
- CNTA N/A
- EPS
- TNDM N/A
- CNTA N/A
- Revenue
- TNDM $854,351,000.00
- CNTA $6,853,000.00
- Revenue This Year
- TNDM $23.61
- CNTA N/A
- Revenue Next Year
- TNDM $10.79
- CNTA N/A
- P/E Ratio
- TNDM N/A
- CNTA N/A
- Revenue Growth
- TNDM 10.75
- CNTA N/A
- 52 Week Low
- TNDM $17.33
- CNTA $5.58
- 52 Week High
- TNDM $53.69
- CNTA $18.74
- Technical
- Relative Strength Index (RSI)
- TNDM 26.79
- CNTA 49.07
- Support Level
- TNDM $29.90
- CNTA $15.15
- Resistance Level
- TNDM $35.50
- CNTA $18.74
- Average True Range (ATR)
- TNDM 1.79
- CNTA 0.88
- MACD
- TNDM -0.18
- CNTA 0.10
- Stochastic Oscillator
- TNDM 0.73
- CNTA 35.68
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.